Analyst Price Target Update on Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares are expected to touch $1 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 0.5. The target price could hit $2 on the higher end and $1 on the lower end.

For the current week, the company shares have a recommendation consensus of Buy.

Peregrine Pharmaceuticals (NASDAQ:PPHM) : On Monday heightened volatility was witnessed in Peregrine Pharmaceuticals (NASDAQ:PPHM) which led to swings in the share price. The stock opened for trading at $0.459 and hit $0.4627 on the upside , eventually ending the session at $0.4493, with a gain of 0.88% or 0.0039 points. The heightened volatility saw the trading volume jump to 1,578,814 shares. The 52-week high of the share price is $1.42 and the company has a market cap of $105 million. The 52-week low of the share price is at $0.2934 .

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.